Two roads for oncolytic immunotherapy development

by Howard L. Kaufman, Praveen K. Bommareddy
Published 2019-02-01

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade

by Praveen K. Bommareddy, Samuel D. Rabkin, Howard L. Kaufman
Published 2019-04-01

Clinical landscape of oncolytic virus research in 2020

by Howard L Kaufman, Rizwan Haq, Nicholas Macedo, David M Miller
Published 2020-07-01

Immunotherapy for Merkel cell carcinoma: a turning point in patient care

by Isaac S. Chan, Shailender Bhatia, Howard L. Kaufman, Evan J. Lipson
Published 2018-03-01

Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma

by Praveen K. Bommareddy, Andrew Zloza, Samuel D. Rabkin, Howard L. Kaufman
Published 2019-07-01

High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma

by Ann W. Silk, Ann W. Silk, Howard L. Kaufman, Howard L. Kaufman, Howard L. Kaufman, Brendan Curti, Janice M. Mehnert, Kim Margolin, David McDermott, Joseph Clark, Jenna Newman, Praveen K. Bommareddy, Praveen K. Bommareddy, Lisa Denzin, Lisa Denzin, Lisa Denzin, Saltanat Najmi, Saltanat Najmi, Azra Haider, Azra Haider, Weichung Shih, Michael P. Kane, Andrew Zloza, Andrew Zloza
Published 2020-01-01

Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma

by Dirk Schadendorf, Paul Nghiem, Shailender Bhatia, Axel Hauschild, Philippe Saiag, Lisa Mahnke, Subramanian Hariharan, Howard L. Kaufman
Published 2017-10-01

Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit

by Howard L Kaufman, Sara Pai, David Blaisdell, Rachel Brodie, Heidi Finnes, Michele Galioto, Roxanne E Jensen, Tom Valuck
Published 2020-06-01

Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials

by Howard L. Kaufman, Robert H. I. Andtbacka, Frances A. Collichio, Michael Wolf, Zhongyun Zhao, Mark Shilkrut, Igor Puzanov, Merrick Ross
Published 2017-09-01

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

by Robert H. I. Andtbacka, Frances Collichio, Kevin J. Harrington, Mark R. Middleton, Gerald Downey, Katarina Ӧhrling, Howard L. Kaufman
Published 2019-06-01

The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)

by Howard L. Kaufman, Michael K. Wong, Gregory A. Daniels, David F. McDermott, Sandra Aung, James N. Lowder, Michael A. Morse
Published 2014-03-01

Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1

by Suzanne Thomas, Linta Kuncheria, Victoria Roulstone, Joan N. Kyula, David Mansfield, Praveen K. Bommareddy, Henry Smith, Howard L. Kaufman, Kevin J. Harrington, Robert S. Coffin
Published 2019-08-01

The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting

by Howard L. Kaufman, Michael B. Atkins, Adam P. Dicker, Heather S. Jim, Louis P. Garrison, Roy S. Herbst, William T. McGivney, Steven Silverstein, Jon M. Wigginton, Peter P. Yu
Published 2017-04-01

The promise of Immuno-oncology: implications for defining the value of cancer treatment

by Howard L. Kaufman, Michael B. Atkins, Prasun Subedi, James Wu, James Chambers, T. Joseph Mattingly, Jonathan D. Campbell, Jeff Allen, Andrea E. Ferris, Richard L. Schilsky, Daniel Danielson, J. Leonard Lichtenfeld, Linda House, Wendy K. D. Selig
Published 2019-05-01

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry

by Brendan Curti, Gregory A. Daniels, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Theodore F. Logan, Jatinder Singh, Meenu Kaur, Theresa L. Luna, Nancy Gregory, Michael A. Morse, Michael K. K. Wong, Janice P. Dutcher
Published 2017-12-01

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial

by Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P. D’Angelo, Kent C. Shih, Céleste Lebbé, Michele Milella, Isaac Brownell, Karl D. Lewis, Jochen H. Lorch, Anja von Heydebreck, Meliessa Hennessy, Paul Nghiem
Published 2018-01-01

Immune oncology, immune responsiveness and the theory of everything

by Tolga Turan, Deepti Kannan, Maulik Patel, J. Matthew Barnes, Sonia G. Tanlimco, Rongze Lu, Kyle Halliwill, Sarah Kongpachith, Douglas E. Kline, Wouter Hendrickx, Alessandra Cesano, Lisa H. Butterfield, Howard L. Kaufman, Thomas J. Hudson, Davide Bedognetti, Francesco Marincola, Josue Samayoa
Published 2018-06-01

Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee

by Howard L Kaufman, Steven A Rosenberg, Adekunle Odunsi, Pranav Murthy, Piyush K Agarwal, Stephen Broderick, Peter E Fecci, Stephanie L Goff, Matthew M Grabowski, Rogerio I Neves, Sara I Pai, Sangeetha Prabhakaran, Ragheed Saoud, Joseph Skitzki, John B Sunwoo, Cecilia CS Yeung
Published 2020-07-01

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)

by Paolo A. Ascierto, James Brugarolas, Luigi Buonaguro, Lisa H. Butterfield, David Carbone, Bruno Daniele, Robert Ferris, Bernard A. Fox, Jérôme Galon, Cesare Gridelli, Howard L. Kaufman, Christopher A. Klebanoff, Ignacio Melero, Paul Nathan, Chrystal M. Paulos, Marco Ruella, Ryan Sullivan, Hassane Zarour, Igor Puzanov
Published 2018-07-01

Correction: Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy

by Dmitriy Zamarin, Howard L Kaufman, Dobrin Draganov, Sofia R Gameiro, Ilio Vitale, Sandy Adjemian, Aitziber Buqué Martinez, Timothy A Chan, Richard L Edelson, Lucia Gabriele, Encouse Golden, Kevin J Harrington, Dewan Md Sakib Hossain, Michael Karin, Juan Jose Lasarte, Sherene Loi, Gwenola Manic, Alan A Melcher, Karen L Mossman, Maria Rescigno, Chiara Riganti, Antonella Sistigu, Bryan E Strauss, Kazuki Tatsuno, Stefaan W van Gool, Peter Vandenabeele
Published 2020-06-01